

Title (en)
COMPOSITIONS COMPRISING CGMP/PDE5 INHIBITOR FOR TRANSDERMAL DELIVERY TO THE ERECTILE TISSUE OF THE PENIS

Title (de)
ZUSAMMENSETZUNGEN ENTHALTEND CGMP-PDE5-HEMMER ZUR TRANSDERMALEN VERABREICHUNG ZUR EREKTILGEWEBE DES PENISES

Title (fr)
COMPOSITIONS COMPRENANT UN INHIBITEUR DE CGMP PDE5 POUR ADMINISTRATION TRANSDERMIQUE AU TISSU ERECTILE DU PENIS

Publication
EP 1404336 A1 20040407 (EN)

Application
EP 01274318 A 20011127

Priority
• IN 0100210 W 20011127
• IN 551MU2001 A 20010614
• IN 552MU2001 A 20010614

Abstract (en)
[origin: WO02102385A1] The invention relates to a pharmaceutical composition comprising cyclic guanosine monophosphate phosphodiesterase type 5 (cGMP PDE5) inhibitor, sildenafil citrate, pharmaceutically acceptable solubilisers and penetration enhancers, along with thickening agents, buffers, emulsifiers and pharmaceutically acceptable surfactants and preservatives, for transdermal delivery to the erectile tissue of the penis, a process of preparing the said composition and method for treatment of erectile dysfunction / vasculogenic impotence by direct/topical application of the transdermal composition to the tissues covering the corpus cavernosum and to the glans penis. The transdermal delivery vehicle for topical application of the composition according to this invention may be in various forms such as gels, ointments, creams, lotions, emulsions and sprays.

IPC 1-7
A61K 31/505; **A61K 9/00**; **A61K 9/06**; **A61P 15/10**

IPC 8 full level
A61K 9/00 (2006.01); **A61K 31/519** (2006.01); **A61P 15/10** (2006.01)

CPC (source: EP)
A61K 9/0014 (2013.01); **A61K 9/0034** (2013.01); **A61K 31/519** (2013.01); **A61P 15/10** (2017.12)

Citation (search report)
See references of WO 02102385A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 02102385 A1 20021227; EP 1404336 A1 20040407

DOCDB simple family (application)
IN 0100210 W 20011127; EP 01274318 A 20011127